Trial Site Detail

 

Drug:
SF1126
Trial:
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors
Conditions: Solid Tumors
Trial Status:
Ongoing, but not recruiting

 

Indiana University Simon Cancer Center

535 Barnhill Drive     
Indianapolis , IN 46202
USA

 

Principal Investigator:
E. Gabriela Chiorean, MD
Contact:
Mary Jane Waddell, RN, CCRC 317-274-7119 mjwaddell@iupui.edu Jennifer M Funke, MS 317-278-0328 jmfunke@iupui.ed
Activation Status of this Site:
Closed
Notes about this Site:
Indiana University Simon Cancer Center Website:
http://cancer.iu.edu/cancer/trials/findtrials.php?category=disease

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.